Clinical Trial

A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared to BFF in Participants of 4 to Less Than 12 Years of Age With Asthma

Study acronym: FAROS
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the effect of 2 different GP metered dose inhaler (MDI) doses relative to placebo MDI as add-on treatment to BFF MDI on lung function in participants 4 to less than 12 years of age with asthma.
Protocol Amendment History 1 change
critical Recruitment opened 2026-04-23
Trial Details
NCT Number NCT07525375
Lead Sponsor AstraZeneca
Conditions Asthma
Enrollment 69 participants
Start Date 2026-04-14
Primary Completion 2029-05-23 (estimated)
Study Completion 2029-05-23 (estimated)
Updated on ClinicalTrials.gov 2026-04-22